Overview of early response assessment in lymphoma with FDG-PET
暂无分享,去创建一个
[1] Klemens Scheidhauer,et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Martin Hutchings,et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.
[3] Otto S Hoekstra,et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Fisher,et al. New treatment options have changed the survival of patients with follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Maloney. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. O'Doherty,et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] R. Hustinx,et al. Positron emission tomography imaging for lymphoma , 2005, Current opinion in oncology.
[8] Emmanuel Itti,et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.
[9] V. Diehl,et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Y. Erdi,et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] N. Mikhaeel,et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Yahalom,et al. Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT) , 2005, European journal of haematology. Supplementum.
[13] M. M. Mac Manus,et al. Initial staging of lymphoma with positron emission tomography and computed tomography. , 2005, Seminars in nuclear medicine.
[14] J. Raemaekers,et al. The EORTC strategy in the treatment of Hodgkin's lymphoma , 2005, European journal of haematology. Supplementum.
[15] P. Zinzani. Lymphoma: diagnosis, staging, natural history, and treatment strategies. , 2005, Seminars in oncology.
[16] 山根 登茂彦. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas , 2005 .
[17] K. Miles,et al. Blood flow–metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[18] M. Heldmann,et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] S. Ito,et al. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] L. Specht,et al. FDG-PET in the clinical management of Hodgkin lymphoma. , 2004, Critical reviews in oncology/hematology.
[21] J. Richter,et al. Positron Emission Tomography Using 18F-Fluorodeoxyglucose for the Evaluation of Residual Hodgkin's Disease Mediastinal Masses , 2004, Leukemia & lymphoma.
[22] Thomas F Hany,et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? , 2004, Radiology.
[23] M. Baccarani,et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients , 2004, British Journal of Cancer.
[24] B. Beuthien-Baumann,et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma , 2004, British Journal of Cancer.
[25] A. D. Van den Abbeele,et al. FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients with de novo Hodgkin Lymphoma: A Blinded Comparison , 2004, Leukemia & lymphoma.
[26] A. Lammertsma,et al. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non‐Hodgkin's lymphoma , 2003, British journal of haematology.
[27] E. Vellenga,et al. Predictive value of early 18F‐fluoro‐deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma , 2003, British journal of haematology.
[28] M. Phelps,et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. , 2003, Chest.
[29] F. Bénard,et al. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] M. Tomas,et al. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] R. Hicks,et al. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. , 2003, Clinical lymphoma.
[32] Danny Rischin,et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] O. Israel,et al. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[34] J. Eary,et al. [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[35] Patrick Dupont,et al. [18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[36] E. Yoshikawa,et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[37] Johan Nuyts,et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] P. Dupont,et al. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] J. Leonard,et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] V. Diehl,et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] R. Fisher,et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. , 2002, The American journal of medicine.
[42] M. Glabbeke,et al. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. , 2002, European journal of cancer.
[43] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[44] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[45] B Beuthien-Baumann,et al. Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma , 2001, British journal of haematology.
[46] U. Cremerius,et al. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma , 2001, Nuklearmedizin.
[47] P. Dupont,et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] A. Lammertsma,et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods , 2000, European Journal of Nuclear Medicine.
[49] Olker,et al. A PROGNOSTIC SCORE FOR ADVANCED HODGKIN ’ S DISEASE , 2000 .
[50] S. Hain,et al. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[51] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[52] G. Jerusalem,et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.
[53] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] J. Armitage,et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.
[55] M. Greco,et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation , 1998, European Journal of Nuclear Medicine.
[56] M Schwaiger,et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.
[57] M. M. Mac Manus,et al. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] B. Glimelius,et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[59] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[60] L G Strauss,et al. The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[61] M Tubiana,et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.